Anyang-si
Anyang-si
Anyang-si, Gyeonnggi-do, South Korea1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML | Chronic Phase Ph+ Chronic Myeloid Leukemia | Active, not recruiting | Not stated | 2026-09-03 | NCT06665412 |